Reviewed on 3/2/2022

Generic Name: Repaglinide

Brand Name: Prandin

Drug Class: Antidiabetics, Meglitinides Derivatives

What Is Repaglinide and How Does It Work?

Repaglinide is a prescription medication used for the treatment of type 2 diabetes mellitus.

  • Repaglinide is available under the following different brand names: Prandin

What Are Dosages of Repaglinide?

Adult dosage


  • 0.5mg
  • 1mg
  • 2mg

Type 2 Diabetes Mellitus

Adult dosage

Starting dose

  • HbA1c  below 8%: 0.5 mg orally before each meal
  • HbA1c above 8%: 1-2 mg orally before each meal

Dosage range

  • Dose range: 0.5-4 mg before meals
  • Maximum daily dose: Not to exceed 16 mg/day

Dosage Considerations – Should be Given as Follows: 

  • See “Dosages”

What Are Side Effects Associated with Using Repaglinide?

Common side effects of Repaglinide include:

Serious side effects of Repaglinide include:

  • hives,
  • difficulty breathing,
  • swelling of the face, lips, tongue, or throat,
  • severe pain in the upper stomach spreading to the back,
  • nausea,
  • vomiting,
  • fast heart rate,
  • pale or yellowed skin,
  • dark-colored urine,
  • fever,
  • confusion,
  • weakness,
  • sore throat,
  • burning in the eyes,
  • skin pain, and
  • red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling

Rare side effects of Repaglinide include:

  • none 
This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

What Other Drugs Interact with Repaglinide?

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns.

What Are Warnings and Precautions for Repaglinide?


  • Hypersensitivity to repaglinide
  • Diabetic ketoacidosis
  • Type I diabetes mellitus
  • Coadministration of gemfibrozil results in increased repaglinide plasma concentration (8-fold increase); may lead to a severe hypoglycemia

Effects of drug abuse

  • None

Short-Term Effects

  • See “What Are Side Effects Associated with Using Repaglinide?”

Long-Term Effects

  • See “What Are Side Effects Associated with Using Repaglinide?”


  • Stress due to infection, fever, trauma, or surgery; may need to discontinue if exposed to stress
  • Hepatic/renal insufficiency
  • Patients at risk of severe hypoglycemia: Elderly, debilitated, or malnourished; adrenal or pituitary insufficiency
  • Myocardial ischemia reported in patients treated concomitantly with NPH-insulin; not indicated for use in combination with NPH-insulin
  • Use caution in elderly and malnourished patients
  • Pregnancy or lactation
  • The use of sulfonylureas may be associated with increased cardiovascular events
  • Drugs that inhibit organic anion transporting protein OATP1B1 (e.g., cyclosporine) may increase plasma concentrations of repaglinide, which is a substrate for active hepatic uptake transporter OATP1B1

Pregnancy and Lactation

  • Limited available data from case reports and case series have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal, or fetal outcomes in women taking repaglinide while pregnant
  • Clinical considerations
  • Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications
  • Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity
  • Lactation
    • No data on the presence of repaglinide in human milk, the effects on the breastfeeding infant, or the effects on milk production
    • Because of the potential for hypoglycemia in breastfed infants, repaglinide is not recommended for use when breastfeeding.
Medscape. Repaglinide.

Health Solutions From Our Sponsors